Top news from MedWatch this week
![Photo: MedWatch](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article12791283.ece/ALTERNATES/schema-16_9/doc7eok1wt4jdl13ye5emaw.jpg)
Monday
Novo Nordisk renounces orphan drug title for potential blockbuster
GN could be potential acquisition target, says bank
Bavarian CFO predicts another record-breaking year ahead
Bavarian Nordic breaks even in preliminary financial update
Danish medtech firm partners with German giant to eliminate needles in blood sugar testing
Tuesday
Ambu silent on Russian exit issues
Bavarian Nordic ditches debt refinancing: ”We don’t need the money right now”
Sales of Novo Nordisk’s Wegovy are off to a good start in 2023
Wednesday
Leo Pharma spokesperson on layoffs of 300 employees: ”It came as a shock”
Leo Pharma to initiate early-stage trial in inflammatory diseases
Thursday
Sonion moves production out of Philippines, fires 1,200 employees
Coloplast is the world’s most sustainable medtech firm in new analysis
Norway denies Novo Nordisk reimbursement for obesity drug
Spokesperson: Laid-off Leo employees have leg-up in job hunt at Novo and Lundbeck
Pharma companies say new US drug price law leaves them in limbo
Friday
Novo Nordisk to invest EUR 130m in French factory
EMA expects antibiotics shortage to improve in coming months
Lilly’s donanemab fails to get early FDA approval for Alzheimer’s
Moderna on RSV vaccine candidate: ”We know it’s very safe, and now we see it’s effective, too”